2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Expert faculty review and share their insights and perspectives on key findings in lymphomas and chronic lymphocytic leukemia presented at the 2020 ASH Annual Meeting.
Jeremy S. Abramson, MD, MMSc
John M. Burke, MD
Jeff Sharman, MD

Lymphomas and Chronic Lymphocytic Leukemia

Slidesets TRANSCEND NHL 001: R/R MCL Cohort of Phase I Study of Lisocabtagene Maraleucel
Slidesets CAPTIVATE: Updated Results From the Phase II Trial of First-line Ibrutinib Plus Venetoclax for CLL/SLL
Slidesets MURANO 5-Yr Analysis: Fixed-Duration Venetoclax + Rituximab vs Bendamustine + Rituximab in R/R CLL
Slidesets Phase Ib ACE-CL-003: Acalabrutinib Combined With Venetoclax and Obinutuzumab or Rituximab in Treatment-Naive or Relapsed/Refractory CLL
Slidesets Predictors of Response to Third-Line Tazemetostat in Relapsed/Refractory Follicular Lymphoma
Slidesets UNITY-NHL: Umbralisib Monotherapy in Patients With R/R Indolent NHL
Slidesets Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in CLL
Slidesets CITADEL-204 Phase II Trial of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed/Refractory Marginal Zone Lymphoma
Slidesets Phase I Study of Odronextamab, a Novel Bispecific Antibody Targeting CD3 and CD20, for Patients With Heavily Pretreated B-Cell NHL
Slidesets SGN35-015: Phase II Study of Frontline Brentuximab Vedotin ± Second Agent for Older Patients With cHL Ineligible for Standard CT
Slidesets Phase I/II BRUIN Trial of LOXO-305 in Previously Treated Patients With CLL/SLL
Slidesets UNITY-CLL: Phase III Trial of Umbralisib + Ublituximab vs Obinutuzumab + Chlorambucil in Patients With CLL
Slidesets TRANSCEND CLL 004: Phase I Results With Lisocabtagene Maraleucel + Ibrutinib in Relapsed/Refractory CLL/SLL
Slidesets ZUMA-5: Phase II Study of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma
Slidesets Phase I Trial of Mosunetuzumab Bispecific Antibody in Multiply Relapsed Follicular Lymphoma

Review expert perspectives on the most clinically relevant data on indolent and aggressive lymphomas presented at the 2020 ASH annual meeting.

John M. Burke, MD Jeff Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: February 26, 2021 Expired: No longer available for credit

In this commentary, Jeremy S. Abramson, MD, MMSc, discusses the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Jeremy S. Abramson, MD, MMSc Released: March 11, 2021

Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Jeremy S. Abramson, MD, MMSc Released: March 26, 2021
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seagen
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings